CTX213 Trademark

Trademark Overview

On Monday, January 13, 2025, a trademark application was filed for CTX213 with the United States Patent and Trademark Office. The USPTO has given the CTX213 trademark a serial number of 98955696. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, January 13, 2025. This trademark is owned by CRISPR Therapeutics AG. The CTX213 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes

gene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of stem cell therapy for the treatment of diabetes
ctx213

General Information

Serial Number98955696
Word MarkCTX213
Filing DateMonday, January 13, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateMonday, January 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesCells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes
Goods and Servicesgene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of stem cell therapy for the treatment of diabetes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 13, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 13, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressZUG V8 6300
CH

Trademark Events

Event DateEvent Description
Monday, January 13, 2025NEW APPLICATION ENTERED
Monday, January 13, 2025APPLICATION FILING RECEIPT MAILED

Related Keywords

treatment diabetes therapy gene namely stem field cell research pharmaceutical